Presenters: Dr Prudence Scott
Topic: “Are Phase 3 trials obsolete?”
Rationally designed targeted therapies to treat cancer have led to unprecedented improvements in treatment outcomes compared with existing standards of care. The resulting demand for earlier access from patients, clinicians and the pharmaceutical industry has led to a paradigm shift in clinical trial design and the evidence required for regulatory approval of medicines.
This has brought challenges and opportunities, and these will be presented, both from a global and Australian perspective, based on what was learnt during nearly 3 years as Director of the Oncology/Haematology Evaluation Unit at the Therapeutic Goods Administration.
Date: Wednesday 2 November 2016
Time: 12.30pm to 1.30pm
Venue: Main Lecture Theatre, Monash Medical Centre, Clayton.